Horauf J, Singh A, Voth M, Moheimani H, Schindler C, Relja B
Diagnostics (Basel). 2025; 15(2).
PMID: 39857063
PMC: 11764008.
DOI: 10.3390/diagnostics15020179.
Ma S, Li X, Wu C, Wulayin K, Li M, Zhou L
BMC Infect Dis. 2024; 24(1):1214.
PMID: 39468469
PMC: 11520826.
DOI: 10.1186/s12879-024-10114-8.
Gaffar S, Aathirah A
Biomolecules. 2023; 13(12).
PMID: 38136624
PMC: 10741572.
DOI: 10.3390/biom13121753.
Xue M, Yao T, Xue M, Francis F, Qin Y, Jia M
Metabolites. 2022; 12(8).
PMID: 36005631
PMC: 9415018.
DOI: 10.3390/metabo12080759.
Duttaroy A, Basak S
Front Physiol. 2022; 12:787848.
PMID: 35126178
PMC: 8811195.
DOI: 10.3389/fphys.2021.787848.
Pathophysiological and diagnostic importance of fatty acid-binding protein 1 in heart failure with preserved ejection fraction.
Harada T, Araki T, Sunaga H, Kagami K, Yoshida K, Kato T
Sci Rep. 2021; 11(1):21175.
PMID: 34707207
PMC: 8551161.
DOI: 10.1038/s41598-021-00760-2.
Rapid and sensitive detection of L-FABP for prediction and diagnosis of acute kidney injury in critically ill patients by chemiluminescent immunoassay.
Sun T, Qu S, Huang T, Ping Y, Lin Q, Cao Y
J Clin Lab Anal. 2021; 35(11):e24051.
PMID: 34651352
PMC: 8605162.
DOI: 10.1002/jcla.24051.
Adipocyte Fatty Acid-Binding Protein as a Predictor of Outcome in Alcohol-induced Acute-On-Chronic Liver Failure.
Kulkarni A, Sharma M, Kumar P, Simhadri V, Sowmya T, Mitnala S
J Clin Exp Hepatol. 2021; 11(2):201-208.
PMID: 33746445
PMC: 7953014.
DOI: 10.1016/j.jceh.2020.07.010.
Prognostic impact of elevated fatty acid-binding protein 1 in patients with heart failure.
Kagami K, Sunaga H, Sorimachi H, Harada T, Yoshida K, Kato T
ESC Heart Fail. 2021; 8(2):1494-1501.
PMID: 33539661
PMC: 8006713.
DOI: 10.1002/ehf2.13239.
Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
Lu Y, Chang C, Wang C, Hung W, Tsai I, Tang W
Int J Med Sci. 2020; 17(2):182-190.
PMID: 32038102
PMC: 6990891.
DOI: 10.7150/ijms.40417.
Serum Liver-Type Fatty Acid-Binding Protein Is a Possible Prognostic Factor in Human Chronic Liver Diseases From Chronic Hepatitis to Liver Cirrhosis and Hepatocellular Carcinoma.
Eguchi A, Hasegawa H, Iwasa M, Tamai Y, Ohata K, Oikawa T
Hepatol Commun. 2019; 3(6):825-837.
PMID: 31168516
PMC: 6545868.
DOI: 10.1002/hep4.1350.
The Importance of Liver-Fatty Acid Binding Protein in Diagnosis of Liver Damage in Patients with Acute Hepatitis.
Cakir O, Toker A, Ataseven H, Demir A, Polat H
J Clin Diagn Res. 2017; 11(4):OC17-OC21.
PMID: 28571184
PMC: 5449830.
DOI: 10.7860/JCDR/2017/24958.9621.
Drug-induced liver injury: recent advances in diagnosis and risk assessment.
Kullak-Ublick G, Andrade R, Merz M, End P, Benesic A, Gerbes A
Gut. 2017; 66(6):1154-1164.
PMID: 28341748
PMC: 5532458.
DOI: 10.1136/gutjnl-2016-313369.
Elevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failure.
Karvellas C, Speiser J, Tremblay M, Lee W, Rose C
Hepatology. 2016; 65(3):938-949.
PMID: 27859489
PMC: 5319885.
DOI: 10.1002/hep.28945.
Cytokine-like Activity of Liver Type Fatty Acid Binding Protein (L-FABP) Inducing Inflammatory Cytokine Interleukin-6.
Kim H, Gil G, Lee S, Kwak A, Jo S, Kim E
Immune Netw. 2016; 16(5):296-304.
PMID: 27799875
PMC: 5086454.
DOI: 10.4110/in.2016.16.5.296.
Liver Fatty Acid Binding Protein Deficiency Provokes Oxidative Stress, Inflammation, and Apoptosis-Mediated Hepatotoxicity Induced by Pyrazinamide in Zebrafish Larvae.
Zhang Y, Liu K, Hassan H, Guo H, Ding P, Han L
Antimicrob Agents Chemother. 2016; 60(12):7347-7356.
PMID: 27697757
PMC: 5119016.
DOI: 10.1128/AAC.01693-16.
Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury.
Mikus M, Drobin K, Gry M, Bachmann J, Lindberg J, Yimer G
Liver Int. 2016; 37(1):132-140.
PMID: 27224670
PMC: 5215406.
DOI: 10.1111/liv.13174.
Metabolic functions of FABPs--mechanisms and therapeutic implications.
Hotamisligil G, Bernlohr D
Nat Rev Endocrinol. 2015; 11(10):592-605.
PMID: 26260145
PMC: 4578711.
DOI: 10.1038/nrendo.2015.122.
Liver fatty acid-binding protein as a diagnostic marker for non-alcoholic fatty liver disease.
Akbal E, Kocak E, Akyurek O, Koklu S, Batgi H, Senes M
Wien Klin Wochenschr. 2014; 128(1-2):48-52.
PMID: 25447969
DOI: 10.1007/s00508-014-0680-8.